MedTrace Logo

Osteoclast Inhibition and Bone Formation

NCT02554695 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2018-01-05

No results posted yet for this study

Summary

This protocol addresses: 1) How gene expression changes in bone cells are affected by aging? 2) Is aging associated with decreased signaling between bone cells? 3) How does treatment with the osteoporosis medication denosumab affect bone cell signaling?

Conditions

  • Bone Loss
  • Aging

Interventions

DRUG

placebo

subcutaneous saline injection

DRUG

denosumab

single subcutaneous injection of denosumab 60 mg

Sponsors & Collaborators

Principal Investigators

  • Sundeep Khosla, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-20
Primary Completion
2016-10-25
Completion
2016-10-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02554695 on ClinicalTrials.gov